Clinical significance of detecting peripheral blood T lymphocyte subsets in patients with pulmonary adenocarcinoma.
- Author:
Xiao ZHAO
1
;
Xiang YAN
;
Shengjie SUN
;
Zhiyong WU
;
Shunchang JIAO
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; blood; immunology; Adult; Aged; Female; Humans; Leukocyte Common Antigens; metabolism; Lung Neoplasms; blood; immunology; Lymphocyte Count; Male; Middle Aged; T-Lymphocyte Subsets; immunology
- From: Journal of Southern Medical University 2012;32(5):752-754
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical value of T lymphocyte subsets in prediction of chemotherapy responses of patients with pulmonary adenocarcinoma.
METHODSFifty-five chemotherapy-naive patients with pathologically or cytologically confirmed pulmonary adenocarcinoma were examined for peripheral blood T lymphocyte subsets using flow cytometry, including CD3(+) T cells, CD3(+)CD4(+) T cells, CD3(+)CD8(+) T cells, CD45RO(+) T cells and CD45RA(+) T cells.
RESULTSPatients who responded favorably to chemotherapy (CR(+)PR) showed a significantly lower percentage of CD45RA(+) T cells than those who failed to respond to chemotherapy (P=0.04). CD45RO(+) T cell percentage were slightly higher in the response group than in the non-response group, but this difference was not statistically significant (P=0.25). The other T cell subsets, namely CD3(+), CD3(+)CD4(+), and CD3(+)CD8(+) T cells showed no significant differences between the two groups.
CONCLUSIONA high percentage of peripheral blood CD45RA(+) T cells is associated with a poor short-term outcome of chemotherapy in patients with advanced pulmonary adenocarcinoma. Peripheral blood CD45RA(+) T cell level can be a reliable index for predicting chemotherapy efficacy in these patients.
